中文 | English
Return
Total: 86 , 1/9
Show Home Prev Next End page: GO
Author:( Ziming LI)

1.Advance on targeted therapy for the treatment of non-small cell lung cancer

Ziming LI ; Shun LU

Cancer Research and Clinic 2010;22(1):7-10

2.Targeted therapy of lung cancer-data from Asia

Shun LU ; Ziming LI

China Oncology 1998;0(01):-

3.New developments in advanced non-small cell lung cancer

Ziming LI ; Meilin LIAO

China Oncology 2006;0(11):-

4.Inhibition effects of gefitinib on non-small cell lung cancer cell lines in vitro

Zhen CHEN ; Ziming LI ; Zhiwei CHEN

Cancer Research and Clinic 2011;23(6):393-395

5.New hot spots on biomarkers for non-small cell lung cancer

Lan SHEN ; Ziming LI ; Shun LU

Cancer Research and Clinic 2010;22(9):592-594

6.The value of sequential, alternating and consolidation chemotherapy in advanced non-small-cell lung cancer

Lanmei ZHANG ; Ziming LI ; Shun LU

Cancer Research and Clinic 2008;20(5):357-360

7.Microsphere Preparation of The Recombinant Adeno-Associated Virus as A Vector for Gene Therapy of Liver Cancer

Ziming LIU ; Lnan YAN ; Xinxiao LI

Chinese Journal of Bases and Clinics in General Surgery 2003;0(04):-

8.Effect of sulodexide combined with dipyridamole on postoperative period of internal arteriovenous fistulae in patients with chronic renal failure complicating diabetes

Nan OUYANG ; Ziming WAN ; Zhengrong LI ; Xiaogang DU

Chongqing Medicine 2014;(15):1863-1865

9.Establishment of human lung adenocarcinoma multidrug resistance cell lines induced by paclitaxel and the mRNA expressions of DNA pol?,mdr1,mrp1,GST-?,lrp,and topo Ⅱ genes

Zhiju WANG ; Hongkun FAN ; Min LI ; Guoqiang ZHAO ; Ziming DONG

Journal of Xi'an Jiaotong University(Medical Sciences) 1982;0(04):-

10.Construction and Management of Official Websites of Medical Institutions

Ziming MAI ; Bin LI ; Yuehong SU ; Zhongmin REN ; Caisheng HE

Journal of Medical Informatics 2017;38(7):68-71

Sort by Result Analysis

Display Mode

Output Records




File Type





Total: 86 , 1/9 Show Home Prev Next End page: GO